Table 1 Characteristics of patients with pancreatic head adenocarcinoma in the two cohorts (n = 389)
From: Nomogram predicts risk of perineural invasion based on serum biomarkers for pancreatic cancer
Variables | Training cohort | Validation cohort | P value |
|---|---|---|---|
(n = 273) | (n = 116) | ||
Age ≤ 60 years, N (%) | 133 (48.7%) | 60 (51.7%) | 0.587 |
Male, N (%) | 161 (59.0%) | 66 (56.9%) | 0.704 |
BMI, mean (SD), kg/m2 | 23.0 (3.0) | 23.43 (2.9) | 0.153 |
ASA grade ≤ II, N (%) | 233 (85.3%) | 107 (92.2%) | 0.061 |
Biliary infection, N (%) | 9 (3.3%) | 3 (2.6%) | 0.960 |
Obstructive jaundice, N (%) | 136 (49.8%) | 61 (52.6%) | 0.617 |
Weight-loss ≥ 5 kg, N (%) | 34 (12.5%) | 9 (7.8%) | 0.177 |
Preoperative Hb, median (IQR), g/L | 127.0 (118.0, 137.0) | 126.0 (117.0, 138.0) | 0.847 |
Preoperative BG, median (IQR), mmol/L | 5.4 (4.8, 6.7) | 5.8 (5.0, 7.3) | 0.552 |
Preoperative ALB, median (IQR), g/L | 39.1 (36.5, 41.2) | 39.0 (35.6, 41.7) | 0.864 |
Preoperative TBIL, median (IQR), µmol/L | 28.3 (11.1, 165.5) | 29.6 (10.3, 170.4) | 0.857 |
Preoperative CA19-9, median (IQR), U/mL | 121.0 (31.4, 372.2) | 166.1 (39.3, 401.6) | 0.821 |
Preoperative CEA, median (IQR), ng/mL | 3.1 (2.0, 4.5) | 2.7 (1.8, 4.8) | 0.297 |
Preoperative CA125, median (IQR), U/mL | 12.9 (9.4, 19.8) | 13.5 (9.4, 21.3) | 0.812 |
Preoperative FIB, median (IQR), g/L | 3.7 (3.1, 4.6) | 3.5 (3.0, 4.3) | 0.068 |
Maximum tumor size, median (IQR), cm †| 3.0 (2.5, 4.0) | 3.0 (2.5, 4.0) | 0.629 |
Median RFS (95% CI), months | 14.7 (12.9–16.5) | 15.4 (11.3–19.4) | 0.607 |
Median OS (95% CI), months | 24.0 (20.7, 29.6) | 23.8 (19.3, 28.3) | 0.809 |
Postoperative adjuvant therapy, N (%) | 196 (71.8%) | 83(71.5%) | 0.984 |